Tesla's (NASDAQ: TSLA) run-up of around 2,050% over the last three years made a lot of investors quite wealthy, but past performance doesn't predict future returns. And in the past 12 months, two small-cap biotechs have massively outperformed the world's most-memed-about electric car manufacturer.

What's more, these two companies aren't one-hit wonders that just got their first medicines approved -- and they're chasing cutting-edge projects. So if you're looking to park a spare $2,500 somewhere that it could grow, it's worth considering a purchase of one or both of these stocks. Here's why.

Continue reading

Source Fool.com